Tejnaksh Healthcare Limited has made a disclosure to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding international recognition received by its Managing Director.
Dr. Ashish V. Rawandale-Patil, Managing Director of Tejnaksh Healthcare Limited, has been selected as a Mentor for the Technology Innovation Program 2027 (ES-TIP 2027) of the Endourological Society. The Endourological Society is described as a globally recognized international organization in the field of urology.
The Technology Innovation Program aims to support and mentor medical innovations and assist healthcare professionals in developing novel ideas for improving patient care. Promising innovations from the program may be considered for further development and commercialization.
Dr. Ashish Rawandale-Patil has been selected as one of the mentors for the program and is noted as the only urologist from outside the United States to join three other distinguished mentors from leading institutions in the United States.
The company states that this recognition reflects Dr. Rawandale-Patil's contribution to medical innovation and highlights India's growing presence on the global healthcare innovation platform. Tejnaksh Healthcare Limited believes that this prestigious international recognition enhances the reputation and visibility of the company and showcases the global expertise and leadership associated with the Company.
Financial Impact
No financial impact quantified in the disclosure. The disclosure primarily concerns reputational enhancement and international recognition.